Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3Department of Pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chang HM, Chou PY, Chou CH, Tsai HC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	biktarvy bictegravir switching virological failure viremia Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/bc8b363815904e97b9c2de8da22d02e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bc8b363815904e97b9c2de8da22d02e5
record_format	dspace
spelling	oai:doaj.org-article:bc8b363815904e97b9c2de8da22d02e52021-11-23T18:43:01ZOutcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study1178-6973https://doaj.org/article/bc8b363815904e97b9c2de8da22d02e52021-11-01T00:00:00Zhttps://www.dovepress.com/outcomes-after-switching-to-bicftctaf-in-patients-with-virological-fai-peer-reviewed-fulltext-article-IDRhttps://doaj.org/toc/1178-6973Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3Department of Pharmacy and Master Program, Collage of Pharmacy and Health Care, Tajen University, Pingtung, Taiwan; 4Section of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 5National Yang Ming Chiao Tung University, Taipei, Taiwan; 6Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, TaiwanCorrespondence: Hung-Chin TsaiSection of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, #386 Ta-Chung 1st Road, Kaohsiung, 813, TaiwanTel +886-7-3422121 ext. 2029Fax +886-7-346-8292Email hctsai1011@yahoo.com.twChen-Hsi ChouInstitute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, TaiwanEmail chenhsi@mail.ncku.edu.twPurpose: This study evaluated the real-world tolerability and treatment effectiveness of BIC/FTC/TAF in treatment-experienced patients living with HIV-1 in Taiwan, especially in those with viremia at switch.Patients and Methods: This was a retrospective cohort study of adult patients in Taiwan with HIV-1 who received BIC/FTC/TAF from between November 2019 and November 2020. The primary endpoint was the rate of viral suppression (plasma HIV RNA load < 50 copies/mL) while on BIC/FTC/TAF. The secondary endpoints included durability of treatment, incidence of and reasons for discontinuation of BIC/FTC/TAF, and changes in weight and lipid profiles.Results: A total of 175 patients were switched to BIC/FTC/TAF. Among them, 74 patients (42%) were using INSTI based regimen, 34 patients (19%) NNRTI based regimen and 65 patients (37%) with PI based regimen before switching. Before starting BIC/FTC/TAF, 84.6% of the patients were virologically suppressed, of whom 97.3% maintained suppression while on BIC/FTC/TAF. Overall, 15.4% of the patients (n=27) had a detectable viral load before BIC/FTC/TAF, of whom 81.5% achieved and maintained virologic suppression on BIC/FTC/TAF during follow-up. Only two patients discontinued BIC/FTC/TAF due to adverse events, with rash being the predominant cause. By month 12, the median changes in weight was +4 kg (IQR, − 1.8 to 8.2). There were no significant differences from baseline to the end of follow-up in triglycerides (p = 0.07), total cholesterol (p = 0.92), LDL-C (p = 0.12), and HDL-C (p = 0.053).Conclusion: The results of this real-world cohort study suggest that switching to BIC/FTC/TAF may be an option to achieve and maintain virological suppression, even in patients with residual viremia at baseline. Our results also demonstrated a low discontinuation rate, a moderate gain in weight, and no significant increases in lipid levels with BIC/FTC/TAF. However, studies with larger sample sizes are warranted to evaluate the clinical implications of our findings.Keywords: Biktarvy, bictegravir, switching, virological failure, viremiaChang HMChou PYChou CHTsai HCDove Medical Pressarticlebiktarvybictegravirswitchingvirological failureviremiaInfectious and parasitic diseasesRC109-216ENInfection and Drug Resistance, Vol Volume 14, Pp 4877-4886 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biktarvy bictegravir switching virological failure viremia Infectious and parasitic diseases RC109-216
spellingShingle	biktarvy bictegravir switching virological failure viremia Infectious and parasitic diseases RC109-216 Chang HM Chou PY Chou CH Tsai HC Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
description	Hui-Min Chang,1– 3 Pei-Yun Chou,4,5 Chen-Hsi Chou,2 Hung-Chin Tsai4– 6 1Department of Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 2Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 3Department of Pharmacy and Master Program, Collage of Pharmacy and Health Care, Tajen University, Pingtung, Taiwan; 4Section of Infectious Diseases, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 5National Yang Ming Chiao Tung University, Taipei, Taiwan; 6Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, TaiwanCorrespondence: Hung-Chin TsaiSection of Infectious Diseases, Department of Medicine, Kaohsiung Veterans General Hospital, #386 Ta-Chung 1st Road, Kaohsiung, 813, TaiwanTel +886-7-3422121 ext. 2029Fax +886-7-346-8292Email hctsai1011@yahoo.com.twChen-Hsi ChouInstitute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, TaiwanEmail chenhsi@mail.ncku.edu.twPurpose: This study evaluated the real-world tolerability and treatment effectiveness of BIC/FTC/TAF in treatment-experienced patients living with HIV-1 in Taiwan, especially in those with viremia at switch.Patients and Methods: This was a retrospective cohort study of adult patients in Taiwan with HIV-1 who received BIC/FTC/TAF from between November 2019 and November 2020. The primary endpoint was the rate of viral suppression (plasma HIV RNA load < 50 copies/mL) while on BIC/FTC/TAF. The secondary endpoints included durability of treatment, incidence of and reasons for discontinuation of BIC/FTC/TAF, and changes in weight and lipid profiles.Results: A total of 175 patients were switched to BIC/FTC/TAF. Among them, 74 patients (42%) were using INSTI based regimen, 34 patients (19%) NNRTI based regimen and 65 patients (37%) with PI based regimen before switching. Before starting BIC/FTC/TAF, 84.6% of the patients were virologically suppressed, of whom 97.3% maintained suppression while on BIC/FTC/TAF. Overall, 15.4% of the patients (n=27) had a detectable viral load before BIC/FTC/TAF, of whom 81.5% achieved and maintained virologic suppression on BIC/FTC/TAF during follow-up. Only two patients discontinued BIC/FTC/TAF due to adverse events, with rash being the predominant cause. By month 12, the median changes in weight was +4 kg (IQR, − 1.8 to 8.2). There were no significant differences from baseline to the end of follow-up in triglycerides (p = 0.07), total cholesterol (p = 0.92), LDL-C (p = 0.12), and HDL-C (p = 0.053).Conclusion: The results of this real-world cohort study suggest that switching to BIC/FTC/TAF may be an option to achieve and maintain virological suppression, even in patients with residual viremia at baseline. Our results also demonstrated a low discontinuation rate, a moderate gain in weight, and no significant increases in lipid levels with BIC/FTC/TAF. However, studies with larger sample sizes are warranted to evaluate the clinical implications of our findings.Keywords: Biktarvy, bictegravir, switching, virological failure, viremia
format	article
author	Chang HM Chou PY Chou CH Tsai HC
author_facet	Chang HM Chou PY Chou CH Tsai HC
author_sort	Chang HM
title	Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
title_short	Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
title_full	Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
title_fullStr	Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
title_full_unstemmed	Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
title_sort	outcomes after switching to bic/ftc/taf in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/bc8b363815904e97b9c2de8da22d02e5
work_keys_str_mv	AT changhm outcomesafterswitchingtobicftctafinpatientswithvirologicalfailuretoproteaseinhibitorsornonnucleosidereversetranscriptaseinhibitorsarealworldcohortstudy AT choupy outcomesafterswitchingtobicftctafinpatientswithvirologicalfailuretoproteaseinhibitorsornonnucleosidereversetranscriptaseinhibitorsarealworldcohortstudy AT chouch outcomesafterswitchingtobicftctafinpatientswithvirologicalfailuretoproteaseinhibitorsornonnucleosidereversetranscriptaseinhibitorsarealworldcohortstudy AT tsaihc outcomesafterswitchingtobicftctafinpatientswithvirologicalfailuretoproteaseinhibitorsornonnucleosidereversetranscriptaseinhibitorsarealworldcohortstudy
_version_	1718416179354140672

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study

Ejemplares similares